CytoSorb therapy in ECMO patients – an update
- ECMO, Intensive Care
Chair: Prof. Manu Malbrain, Brussels/Belgium and Prof. Ralf Muellenbach, Kassel/Germany
- Overwhelming inflammation in ECMO – when and how to face it?
Prof. Leonardo Gottin, Verona/Italy - Early use of cytokine adsorption in severe COVID-19 pneumonia requiring VV-ECMO – first results from the CYCOV trial
Dr. Alexander Supady, Freiburg/Germany - Can VV-ECMO patients with severe pneumogenic sepsis benefit from CytoSorb therapy? Results from a retrospective study
Dr. Ali Akil, Ibbenbueren/Germany
Share
|
CytoSorb therapy in ECMO patients – an update
Share
|
Chair: Prof. Manu Malbrain, Brussels/Belgium and Prof. Ralf Muellenbach, Kassel/Germany
- Overwhelming inflammation in ECMO – when and how to face it?
Prof. Leonardo Gottin, Verona/Italy - Early use of cytokine adsorption in severe COVID-19 pneumonia requiring VV-ECMO – first results from the CYCOV trial
Dr. Alexander Supady, Freiburg/Germany - Can VV-ECMO patients with severe pneumogenic sepsis benefit from CytoSorb therapy? Results from a retrospective study
Dr. Ali Akil, Ibbenbueren/Germany
More Videos
Webinar | EuroELSO 2020 Virtual ECMO Day | June 25, 2020
Webinar | The trinity of COVID-19: Immunity, Inflammation and Intervention | May 20th 2020
Webinar | Cytokine adsorption in severely ill COVID-19 patients | April 16th 2020
Webinar | CytoSorb therapy in COVID-19 patients